Central Trust Company’s Inovio Pharmaceuticals INO Stock Holding History

Central Trust Company’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-104	Closed	-$5K	–	1298
2017 Q4	$5K	Hold	104	–	–	﹤0.01%	1089
2017 Q3	$8K	Hold	104	–	–	﹤0.01%	978
2017 Q2	$10K	Hold	104	–	–	﹤0.01%	950
2017 Q1	$8K	Hold	104	–	–	﹤0.01%	994
2016 Q4	$9K	Hold	104	–	–	﹤0.01%	1001
2016 Q3	$12K	Hold	104	–	–	﹤0.01%	927
2016 Q2	$12K	Hold	104	–	–	﹤0.01%	945
2016 Q1	$11K	Hold	104	–	–	﹤0.01%	935
2015 Q4	$8K	Hold	104	–	–	﹤0.01%	999
2015 Q3	$7K	Hold	104	–	–	﹤0.01%	1038
2015 Q2	$10K	Hold	104	–	–	﹤0.01%	1005
2015 Q1	$10K	Hold	104	–	–	﹤0.01%	977
2014 Q4	$11K	Hold	104	–	–	﹤0.01%	959
2014 Q3	$12K	Hold	104	–	–	﹤0.01%	948
2014 Q2	$14K	Buy	+104	New	+$12.3K	﹤0.01%	908

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Central Trust Company's INO Position: Q1 2018 in Review

Central Trust Company sold out of Inovio Pharmaceuticals (INO) in Q1 2018, closing a stake of 104 shares — an estimated $5K sold.

Central Trust Company first reported a position in INO in Q2 2014 and held it in 15 quarters. The position peaked at $14K in Q2 2014. 126 funds tracked by Wall St. Rank hold INO as of Q1 2018.

Central Trust Company reported no remaining Inovio Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Central Trust Company sold 104 Inovio Pharmaceuticals shares in Q1 2018, an estimated $5K.
Central Trust Company first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 15 quarters.
Central Trust Company's Inovio Pharmaceuticals position peaked at $14K in Q2 2014.
126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2018.

Based on Central Trust Company's 13F filing for Q1 2018, filed 4 Apr 2018.